The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
Field/Summary and Commentary
Baker et al.
A general framework for describing various roles for biomarkers in cancer prevention research (early detection, surrogate endpoint, and cohort identification for primary prevention) and the phases in their evaluation.
Surrogate endpoints and FDA’s accelerated approval process.
Sargent et al.
Meta-analytic approach for surrogate validation.
A simple meta-analytic approach for using a binary endpoint to predict the effect of intervention on true endpoint.
Korn et al.
Assessing surrogates as trial endpoints using mixed models.
Weir and Walley
Statistical evaluation of biomarkers as surrogate endpoints: A literature review.
Title: Surrogate endpoints: Wishful thinking or reality?
Finley Austin and Babiss
Where and how could biomarkers be used in 2016?
Qu and Case
Quantifying the indirect treatment effect via surrogate markers.
Desai et al.
Blood pressure as an example of a biomarker that functions as a surrogate.
Initial treatment of HIV Infection: Randomized trials with clinical endpoints are still needed.